Friday, July 10, 2026

pharma · Hepatocellular Carcinoma · Obesity

Hospital Authority

Hospital Authority, Hong is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hepatocellular Carcinoma, Obesity, Acute Kidney Injury, Nasopharyngeal Carcinoma, Coronary Artery Disease. No

Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN HQ
1991 Founded
12,669 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN
Founded
1991
Employees
12,669
Programs
322
Drugs
301
Patents
0
Clinical program

dydrogesterone

Phase 3 · small molecule · Preterm Delivery

dydrogesterone for Preterm Delivery is a Phase 3 program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

← All Hospital Authority, Hong Kong projects Phase 3 small molecule completed

Internal code SPS2016-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Hospital Authority, Hong Kong
Phase
Phase 3
Modality
small_molecule
Indication
Preterm Delivery
Status
completed
Trials
1